Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review
Open accessThe DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognosis, specifically the case fatality and duration, of untreated tuberculosis is important as many patients are not correctly diagnosed and therefore receive inadequate or no treatment. Furthermore, duration and case fatality of tuberculosis are key parameters in interpreting epidemiological data. METHODOLOGY AND PRINCIPAL FINDINGS: To estimate the duration and case fatality of untreated pulmonary tuberculosis in HIV negative patients we reviewed studies from the pre-chemotherapy era. Untreated smear-positive tuberculosis among HIV negative individuals has a 10-year case fatality variously reported between 53% and 86%, with a weighted mean of 70%. Ten-year case fatality of culture-positive smear-negative tuberculosis was nowhere reported directly but can be indirectly estimated to be approximately 20%. The duration of tuberculosis from onset to cure or death is approximately 3 years and appears to be similar for smear-positive and smear-negative tuberculosis. CONCLUSIONS: Current models of untreated tuberculosis that assume a total duration of 2 years until self-cure or death underestimate the duration of disease by about one year, but their case fatality estimates of 70% for smear-positive and 20% for culture-positive smear-negative tuberculosis appear to be satisfactory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Selection of papers. Flowchart schematically showing inclusion and exclusion of papers. Those marked with a * were excluded either because they were referred to at places in the text that did not discuss duration of tuberculosis, tuberculosis mortality, case fatality, life tables or natural history, or because the title indicated that the paper was not about one of these topics; ** for two of these, data were included to the extent mentioned by Berg [115] (see legend of Table 3).](https://figures.cochat.ai/paper-figures/8114c3bf70fd484d9fe91b2b4854751c/natural-history-of-tuberculosis-duration-and-fatality-of-untreated-pulmonary-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the average duration until cure or death is 3 years for untreated patients with tuberculosis,25”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553 · cited 2×
“a 70% CF, as used by WHO and others in their estimates of the burden of tuberculosis [27], seems a reasonable ballpark figure.”
BackgroundMethodSelf-citationTuberculosis and diabetes mellitus: convergence of two epidemics
Dooley, K. E., & Chaisson, R. E. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70282-8 · Cited by 932 · cited 1×
“tuberculosis and progression to tuberculosis disease is influenced by host factors and especially risk of progression depends on the hosts’ immune status, which may be reduced due to concomitant HIV infection, diabetes, and other underlying diseases [27,28].”
BackgroundFluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review
Steingart, K. R., Henry, M., Ng, V., Hopewell, P. C., Ramsay, A., Cunningham, J., Urbanczik, R., Perkins, M., Aziz, M. A., & Pai, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70578-3 · Cited by 798 · cited 1×
“smear, with low sensitivity for paucibacillary disease, is the only available diagnostic tool [6].”
BackgroundThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“Furthermore, Mycobacterium tuberculosis strains resistant to rifampicin and INH might be less fit than drug susceptible strains and therefore lead to longer duration of disease with less mortality [15].”
BackgroundDye, C. (2005) · JAMA · doi:10.1001/jama.293.22.2767 · Cited by 534 · cited 1×
“course) strategy only offer free treatment to smear-positive cases in view of their disproportionate role in tuberculosis transmission and thus their large public health impact [7].”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 1×
“The prognosis of untreated tuberculosis is difficult to study these days as leaving patients untreated, especially in a study setting, is unethical. As an alternative, one could consider, as an approximation, the prognosis of multi-drug resistant (MDR) tuberculosis treated with first line drugs. However, MDR-tuberculo…”
HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm
Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518665 · Cited by 483 · cited 4×
“As regards CF, the review of Payne and Bellamy [143] provided no information on the prognosis of HIV positive MDR-tuberculosis patients.”
BackgroundInfluentialTreatment of Tuberculosis in Patients with Advanced Human Immunodeficiency Virus Infection
Small, P. M., Schecter, G. F., Goodman, P. C., Sande, M. A., Chaisson, R. E., & Hopewell, P. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101313240503 · Cited by 477 · cited 1×
“tuberculosis, of 16 months [145].”
The White Plague: Tuberculosis, Man and Society
(1954) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1954.tb85837.x · Cited by 388
Recurrence in tuberculosis: relapse or reinfection?
Lambert, M.-L., Hasker, E., Deun, A. V., Roberfroid, D., Boelaert, M., & Van der Stuyft, P. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00607-8 · Cited by 225 · cited 1×
“Moreover, of the two possible end points, cure is hard to measure, as relapses are common [140] and establishing cure in untreated tuberculosis patients requires extensive medical investigations.”
Background
Research works printed but not linked: 25
- JA Rutledge, 1919, The ultimate results in 1654 cases of tuberculosis treated at the modern Woodmen of America sanatorium., Am Rev Tuberc, 2, 755
- E Loewenstein, 1931, Die Zuchtung der Tuberkelbazillen aus dem stroemenden Blute., Zentralbl Bakteriol Parasitenkd Infektionskr Hyg, 1, 127
- KA Jensen, 1932, Reinzuchtung und Typenbestimmung von Tuberkelbazillenstammen., Zentralb Bakteriol Parasitenkd Infektionskr Hyg Abt, 1, 222
- GH Hamel, 1928, Jahresversammlung des Deutschen Zentral-komitees zur Bekämpfung der Tuberkulose. Erster Verhandlungstag. (discussions during annual meeting of the German Tuberculosis Control Committee)., Zeitschr Tuberk, 51, 497
- B Meidell, 1931, Die wahrscheinliche Lebensdauer und die Sterblichkeitsmessung., Skandinavisk aktuarietidskrift, 14, 217
- Anonymous, 1936, The expectation of life of the tuberculous., Tubercle, 17, 171
- F Oldenburg, 1931, Gedanken über das Schicksal offentuberkulöser Eisenbahner auf Grund statistischer Erhebungen., Zeitschr Tuberk, 61, 334
- S Phillips, 1964, Relapse in treated cases of pulmonary tuberculosis. II. Six-year follow-up of 109 patients discharged from the hospital with medical approval, 1955-1956., Am Rev Respir Dis, 90, 61
- W May, 1928, Welche Konsequenzen ergeben sich aus der Dauerstatistik der Heilverfahren bei Offentuberkulösen?, Zeitschr Tuberk, 51, 177
- H Ruge, 1909, Dauererfolge nach 10 Jahren bei Lungetuberkulose im Hochgebirge., Zeitsch Tuberk, 15, 146
- E Saegler, 1934, Beitrag zur Frage der Beziehungen zwischen Tuberkulose und Lebensalter., Zeitschr Tuberk, 71, 285
- E Stadler, 1903, Der Einfluss der Lungetuberkulose of Lebensdauer und Erwerbsfähigkeit und der Werth der Volksheilstättenbehandlung., Deutsch Arch Klin Med, 95, 412
- MG Stephens, 1941, Follow-up of 1041 tuberculous patients., Am Rev Tuberc, 44, 451
- PF Holst, 1906, Untersuchungen über die Lebensdauer der Schwindsüchtigen in Norwegen., Deutsch Arch Klin Med, 88, 325
- H Braeuning, 1920, Tuberkulöse Erkrankungen bei Schwestern infolge von Ansteckung im Dienst und ihre Verhütung., Zeitschr Tuberk, 33, 129
- AD De Besche, 1925, Dødeligheten av Lungentuberkulose i Oslo blandt til Byen indflyttede og der fødte Individer., Norsk Magazin for Laegevidenskaben, 86, 1229
- CRNF Van Joost, 1935, Opmerkingen naar aanleiding van een 200 tal met kunstmatige pneumothorax- en een 50 tal met middenrifsverlamming (phrenicusexairesis) behandelde gevallen van longtuberculose., Geneeskund Tijdschr v Ned Indië, 75, 1223
- B Van Vliet, 1963, Analyse van de sterfte aan longtuberculose te Amsterdam in de jaren 1960 en 1961., Ned Tijdschr Geneesk, 107, 2180
- SP Pamra, 1973, Changes in prevalence and incidence of pulmonary tuberculosis in Delhi in recent years., Ind J Tuberc, 20, 57
- CMF Sinding-Larsen, 1937, On the collapse treatment of pulmonary tuberculosis. A clinical adaption and follow-up examination of the material from Vejlefjord Sanatorium, 1906-1932., Acta Med Scand, 91, 39
- S Magnusson, 1938, Über den Verlauf und die Letalität der Tuberkulose in den verschiedenen Altersperioden., Acta Tuberc Scand, 12, 201
- W Münchbach, 1933, Das Schicksal des lungentuberkulösen Erwachsenen. Ergibnisse der Heilstattenbehandlung von annähernd 10000 Männern und Frauen., Tuberkulose-Bibliothek, 49, 64
- H Braeuning, 1936, Prognose der offenen Tuberkulose, Technik der Prognose-stellung und Rentabilität des Heilverfahrens., Zeitschr Tuberk, 75, 305
- H Braeuning, 1933, Die Prognose der offenen Lungentuberkulose., Tuberkulose-Bibliothek, 52, 40
- H Braeuning, 1930, Über die Letalität, Morbidität und Infektionsdauer der offenen Lungentuberkulose., Zeitschr Tuberk, 59, 109
Cited by
Items 501–600 of 630
Reproduzierbarkeit quantitativer Messergebnisse bei Interferon-gamma-Release-Assays im Grenzbereich
Reinhold, L. (2018) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.22790
Ramos, A., & Sandra, G. (2016) · Americanae (AECID Library)
Shaweno, D. (2018) · Minerva Access (University of Melbourne)
Çavuşoğlu, C., & Arslan, A. (2019) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.5222/tmcd.2019.118
“Tedavi almayan tüberküloz hastalarında mortalitenin yüksek olduğu, doğal seyrindeki yayma pozitif tedavisiz akciğer tüberkülozu olgularının 10 yıl içinde %70’inin yaşamını kaybettiği bildirilmiştir(4).”
The Tuberculosis Epidemic in Romania
Socaci, A., Mahler, B., Chiotan, D. I., POPESCU, G. G., Stefan, M., Cioran, N., Benedikt, C. J., Cheikh, N., Fraser, N., Shubber, Z., et al. (2019) · World Bank, Washington, DC eBooks · doi:10.1596/32583
Tóth, S. Z. (2019) · University of Birmingham Institutional Research Archive (University of Birmingham)
Variação temporal da incidência da tuberculose no Brasil e em Portugal
Vilasbôas, S. W. S. L., & Teixeira, M. C. M. (2019) · Revista de Saúde Coletiva da UEFS · doi:10.13102/rscdauefs.v9i0.4519
Duque-Villegas, M. A., Abbadi, B. L., Romero, P. R., Galina, L., Dalberto, P. F., Rodrigues-Junior, V. S., Roth, C. D., Rambo, R. S., de Souza, E. V., Perelló, M. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.02.974360 · Cited by 2
Tuberculosis y Vitamina D: Una Relación Intrigante
Ramirez-Ramos, C. F., Montilla, J. F. S., Correa, S., Restrepo, J. M. T., Méndez, D. A. R., Meneses, N. B., Rivera-Marín, J. D., Tovar, A. P., & Lastra, G. (2017) · Revista Navarra Médica · doi:10.61182/rnavmed.v3n1a5
Current Advances in the Development of Drug and Vaccine for Tuberculosis Prevention and Treatment
Eskeziyaw, B. M. (2020) · Eurasian Journal of Medical Investigation · doi:10.14744/ejmi.2020.31013
Doing things right and knowing what's happening in tuberculosis
Rieder, H. L. (2020) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2020.10.009
Ali, R. M., Thwani, A. N. A., & Dhaer, F. H. (2014) · Diyala Journal for Pure Science
Introduction: An Overview of Host-Directed Therapies for Tuberculosis
Frank, D. J., & Mahon, R. N. (2020) · Springer eBooks · doi:10.1007/978-3-030-56905-1_1 · Cited by 1
Zebrafish Mutagenesis Study of Host Determinants of Mycobacterial Infection Outcome
Televantos, C. (2019) · Apollo (University of Cambridge) · doi:10.17863/cam.58509
Naning, H. (2017) · University of Malaya Students Repository
Calixto, F. M. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.6.2021.tde-09042021-163411
Flick, H., & Wurzinger, G. (2013) · Der Pneumologe · doi:10.1007/s10405-013-0681-8
Targeted nanoparticles for phototherapy.
Winter, P. M. (2011) · PubMed
Sintomas climatéricos em mulheres brasileiras de meia idade
Filho, J. F. L. (2017) · doi:10.47749/t/unicamp.2017.989158
Optimizing Investments in Mozambique's Tuberculosis Response
Program, M. N. T., & Bank, W. (2020) · World Bank, Washington, DC eBooks · doi:10.1596/33907
(2016) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2016.11.027
van Beek, H. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737167210.793570269
The dodecin of Mycobacterium tuberculosis : biological function and biotechnical applications
Bourdeaux, F. A. (2021) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.60946
Flick, H., & Wurzinger, G. (2013) · Humanmedizin kompakt · doi:10.1007/s40355-013-0019-0
Ghatage, S., Shubha, D. B., Latha, S., & Kanganolli, S. R. (2022) · National Journal of Community Medicine · doi:10.55489/njcm.131020222317
Shi, H., & Li, T. (2023) · medRxiv · doi:10.1101/2023.01.18.23284705
“Tuberculosis mostly occurs in the lungs, but various organs throughout the body, such as lymph nodes, bones, kidneys, and brain, can develop the disease [3].”
BackgroundImmunodiagnosis of Tuberculosis: Advantages and Disadvantages
Михайлович, Б. А., Серегина, В. А., Сергеевна, П. Н., & Левянкова, А. Л. (2023) · Клиническая инфектология и паразитология · doi:10.34883/pi.2023.12.1.029
Häcker, B., Otto-Knapp, R., & Bauer, T. T. (2023) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_399-2
Musteikienė, G., Zaveckienė, J., Barkauskienė, D., & Miliauskas, S. (2023) · Pulmonology and allergology · doi:10.37499/pia.1161
Antituberculous Agents for Pediatric Mycobacterial Diseases, and Hearing Loss
Hatipoğlu, N., Arısoy, E. S., & Muñoz, F. M. (2023) · Comprehensive ENT · doi:10.1007/978-3-031-38495-0_70
Muravyeva, A. A., Mikhaylova, Y., & Sterlikov, S. A. (2023) · Social Aspects of Population Health · doi:10.21045/2071-5021-2023-69-3-4
Pathways to end TB- challenges
Arora, V. K., & Chopra, K. K. (2024) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2024.01.008
BAYESIAN MODELLING OF TUBERCULOSIS PREVALENCE IN SOUTH AFRICA. AN OVER-DISPERSION STUDIES
Obaromi, D. A., & Adams, S. O. (2023) · Journal Of Healthcare In Developing Countries · doi:10.26480/jhcdc.02.2023.28.32
Ku, C.-C., MacPherson, P., Khundi, M., Soko, R. N., Feasey, H. R. A., Nliwasa, M., Horton, K. C., Corbett, E. L., & Dodd, P. J. (2021) · Figshare · doi:10.6084/m9.figshare.16969295
Ku, C.-C., MacPherson, P., Khundi, M., Soko, R. N., Feasey, H. R. A., Nliwasa, M., Horton, K. C., Corbett, E. L., & Dodd, P. J. (2021) · Figshare · doi:10.6084/m9.figshare.16969301
Ku, C.-C., MacPherson, P., Khundi, M., Soko, R. N., Feasey, H. R. A., Nliwasa, M., Horton, K. C., Corbett, E. L., & Dodd, P. J. (2021) · Figshare · doi:10.6084/m9.figshare.16969298
Pando, C., Hazel, A., Tsang, L. Y., Razafindrina, K., Andriamiadanarivo, A., Rabetombosoa, R. M., Ambinintsoa, I., Sadananda, G. B., Small, P. M., Knoblauch, A. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23916783
Ku, C.-C., MacPherson, P., Khundi, M., Soko, R. N., Feasey, H. R. A., Nliwasa, M., Horton, K. C., Corbett, E. L., & Dodd, P. J. (2021) · Figshare · doi:10.6084/m9.figshare.16969292
Rambaran, S. (2023) · ResearchSpace (University of KwaZulu-Natal) · doi:10.29086/10413/23009
Chen, S., Rao, W., Fu, L., Liu, G., Zhang, J., Liao, Y., Lv, N., Deng, G., Yang, S., Lin, L., et al. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001255
Alharbi, A. A., Al-Arej, I. M., Alsayegh, A. S., Owias, M. I. Z. A., & Alanezi, B. S. (2019) · International Journal of Health Sciences · doi:10.53730/ijhs.v3ns1.15301
“The 10-year death rate for smear-positive pulmonary tuberculosis is 70% if treatment is not received [5].”
BackgroundSachdeva, R. A., Singh, S., & Sen, M. (2024) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_15_24
Kurt, C. B., Bozok, T., ALTINLI, M. H., Yeşil, E., & Aslan, G. (2025) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.2025011214
“If left untreated, the mortality rate can reach up to 50 percent [4] .”
Genetic control of the transcriptional response to active tuberculosis disease and treatmentPreprint
O'Grady, J. F., Leonard, A. S., Li, H., Fang, L., Pausch, H., Gormley, I. C., Gordon, S. V., & MacHugh, D. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.11.648383
da Silva, F. P., Ramos, J. P., Barbosa, P., Vieira, M., & Raquel Duarte2, 3. (2025) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20250059
Genetic Control of the Transcriptional Response to Active Tuberculosis Disease and TreatmentPreprint
O'Grady, J. F., Leonard, A. S., Li, H., Fang, L., Pausch, H., Gormley, I. C., Gordon, S. V., & MacHugh, D. E. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5237328
Mert, A., Derin, O., Zerdali, E. Y., Kaya, A., Gül, Ö., Borcak, D., Kurt, A. F., Koç, M. M., Kayaaslan, B., Batırel, A. A., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329267
“However, with the World Health Organization (WHO)’s recommended 6-month anti-TB regimen, about 85% of cases can be successfully cured [3].”
Tuberculosis during the COVID-19 Pandemic: Retrospective Analysis in a Tertiary Hospital in Portugal
Matias, E., Oliveira, M., Ceia, F., & Santos, L. (2025) · Advances in Infectious Diseases · doi:10.4236/aid.2025.153032
Sánchez, G. P. V., Gabilanes, G. A., & Echeverría-Valencia, G. (2025) · Revista Científica Multidisciplinar G-nerando · doi:10.60100/rcmg.v6i2.730
A ascensão e a queda dos antibióticos: como seria um mundo sem eles?
Cheng, A. (2023) · The Conversation · doi:10.64628/ade.ttdvaps4s
Genetic control of the transcriptional response to active tuberculosis disease and treatmentPreprint
MacHugh, D. E., O'Grady, J. F., Leonard, A. S., Li, H., Fang, L., Pausch, H., Gormley, I. C., & Gordon, S. V. (2025) · Research Square · doi:10.21203/rs.3.rs-7311967/v1
Kurbatova, E. V., Dooley, K. E., Carr, W., Stout, J. E., Nuermberger, E. L., Phillips, P. P. J., Scott, N. A., Upton, C. M., Ignatius, E. H., Haas, M. K., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108075
Elmeligy, S., Mohsen, E., Nassar, A., Baky, M. H., & Farag, M. A. (2025) · Science and Technology Nexus · doi:10.25259/stn_4_2025
Moharrum, S. A., Bilal, N. E., & Mhmoud, N. A. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.108160
Bioinformatics of Tuberculosis and Post-TB Lung Damage
Ogidi, O. I., Shaikh, S. S., & Barwant, M. M. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-4923-7.ch005
Kuchaka, D. J., Juma, S. P., Shekimweri, E. A., Swema, B. M., Sakasaka, P. A., Mmbaga, B. T., & Sariko, M. (2025) · East African Health Research Journal · doi:10.24248/eahrj.v9i1.823
CLINICAL EFFICACY OF DOSAGE FORMS IN PATIENTS WITH TUBERCULOSIS AND DIABETES: A COMPARATIVE REVIEW
Uzakova, A., Yerlanuly, A., Ergalieva, E. M., Univertisy, A. B. K. R., & Kadirbekov, K. A. (2025) · Chemical Journal of Kazakhstan · doi:10.51580/2025-4.2710-1185.51
Li, W., Zhao, Z., & Sha, W. (2025) · Medicine · doi:10.1097/md.0000000000046555
“[34] WHO recommends a 6-month drug course for anti-TB therapy.”
Pando, C., Hazel, A., Tsang, L. Y., Razafindrina, K., Andriamiadanarivo, A., Rabetombosoa, R. M., Ambinintsoa, I., Sadananda, G. B., Small, P. M., Knoblauch, A. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23916780
Ku, C.-C., MacPherson, P., Khundi, M., Nzawa Soko, R. H., Feasey, H. R. A., Nliwasa, M., Horton, K. C., Corbett, E. L., & Dodd, P. J. (2021) · Figshare · doi:10.6084/m9.figshare.16969289
Clark, R. A., Weerasuriya, C. K., Portnoy, A., Mukandavire, C., Quaife, M., Bakker, R., Scarponi, D., Harris, R. C., Rade, K., Mattoo, S. K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23884337
Kendall, E. A., Hussain, H., Kunkel, A., Kubiak, R. W., Trajman, A., Menzies, R., & Drain, P. K. (2021) · Figshare · doi:10.6084/m9.figshare.17194071
Vesga, J. F., Lienhardt, C., Nsengiyumva, P., Campbell, J. R., Oxlade, O., den Boon, S., Falzon, D., Schwartzman, K., Churchyard, G., & Arinaminpathy, N. (2022) · Figshare · doi:10.6084/m9.figshare.19785625
Pando, C., Hazel, A., Tsang, L. Y., Razafindrina, K., Andriamiadanarivo, A., Rabetombosoa, R. M., Ambinintsoa, I., Sadananda, G. B., Small, P. M., Knoblauch, A. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23916789
Vesga, J. F., Lienhardt, C., Nsengiyumva, P., Campbell, J. R., Oxlade, O., den Boon, S., Falzon, D., Schwartzman, K., Churchyard, G., & Arinaminpathy, N. (2022) · Figshare · doi:10.6084/m9.figshare.19785631
Pando, C., Hazel, A., Tsang, L. Y., Razafindrina, K., Andriamiadanarivo, A., Rabetombosoa, R. M., Ambinintsoa, I., Sadananda, G. B., Small, P. M., Knoblauch, A. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23916777
Vesga, J. F., Lienhardt, C., Nsengiyumva, P., Campbell, J. R., Oxlade, O., den Boon, S., Falzon, D., Schwartzman, K., Churchyard, G., & Arinaminpathy, N. (2022) · Figshare · doi:10.6084/m9.figshare.19785643
Vesga, J. F., Lienhardt, C., Nsengiyumva, P., Campbell, J. R., Oxlade, O., den Boon, S., Falzon, D., Schwartzman, K., Churchyard, G., & Arinaminpathy, N. (2022) · Figshare · doi:10.6084/m9.figshare.19785637
Pando, C., Hazel, A., Tsang, L. Y., Razafindrina, K., Andriamiadanarivo, A., Rabetombosoa, R. M., Ambinintsoa, I., Sadananda, G. B., Small, P. M., Knoblauch, A. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23916786
Vesga, J. F., Lienhardt, C., Nsengiyumva, P., Campbell, J. R., Oxlade, O., den Boon, S., Falzon, D., Schwartzman, K., Churchyard, G., & Arinaminpathy, N. (2022) · Figshare · doi:10.6084/m9.figshare.19785640
Vesga, J. F., Lienhardt, C., Nsengiyumva, P., Campbell, J. R., Oxlade, O., den Boon, S., Falzon, D., Schwartzman, K., Churchyard, G., & Arinaminpathy, N. (2022) · Figshare · doi:10.6084/m9.figshare.19785646
Vesga, J. F., Lienhardt, C., Nsengiyumva, P., Campbell, J. R., Oxlade, O., den Boon, S., Falzon, D., Schwartzman, K., Churchyard, G., & Arinaminpathy, N. (2022) · Figshare · doi:10.6084/m9.figshare.19785634
Implementação de APP para atendimento de "Toma Observada Direta"
Líbano, D. R. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/bddh-xz45
Clark, R. A., Weerasuriya, C. K., Portnoy, A., Mukandavire, C., Quaife, M., Bakker, R., Scarponi, D., Harris, R. C., Rade, K., Mattoo, S. K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23884340
Complejos metálicos con potencial aplicación para el tratamiento de la tuberculosis
Chucho, C. K. G. (2023) · Communities in DSpace (Pontifical Catholic University of Peru)
MARTINS, D. A. D. S. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Ault, R. (2020) · OhioLink ETD Center (Ohio Library and Information Network)
Villegas, M. A. D. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Islam, A. (2024) · BRAC University Institutional Repository (BRAC University)
(2018) · Arizona State University Library Digital Repository (Arizona State University)
Seral, J. C., Martín, C., & Gonzalo Asensio, J. Á. (2023) · Zaguan (University of Zaragoza Repository)
Crombie, I. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-2081-7_10
Jiang, Q., Liu, Z., & Wang, L. (2026) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2026.109640
Klaos, K. (2026) · DSpace repository (University of Tartu)
Rahayu, S. R., Nugroho, A., Ningrum, D. N. A., Merzistya, A. N. A., Wijayantiningrum, T., Simanjuntak, J. S., Maali, M. Z., Hafidh, K. A., Salsabila, A. P., Pranindita, S. K., et al. (2026) · Healthcare Informatics Research · doi:10.4258/hir.2026.32.1.4
“Without treatment, up to 70% of smear-positive and 20% of smear-negative TB patients may die within 10 years [6].”
Abalı, H., & Akyıl, F. T. (2026) · Acibadem Universitesi Saglik Bilimleri Dergisi · doi:10.31067/acusaglik.1821876
Ibrahim, A., Abdullahi, M., Magaji, A. A., Salihu, M., Kudi, C., Garba, B., Sidi, S., Muhammed, M., Gaddafi, M. S., & Dahiru, H. (2026) · European Journal of Microbiology and Infectious Diseases. · doi:10.5455/ejmid.20251123051654
Particulate systems for lung delivery of pyrazinamide for tuberculosis treatment
Pham, D. D. (2014) · theses.fr (ABES) · doi:10.70675/03166a20zd23bz4ca1z8706z5d3f89b3c5dd
Characterization of the immune response to a TLR4-based adjuvant in murine models
Dubois, N. (2016) · theses.fr (ABES) · doi:10.70675/97bd734az4b23z4b66zaa5ezfefd23aa06a3
Modélisation de la pathologie et du traitement de la tuberculose : application à l’isoniazide
Lalande, L. (2016) · theses.fr (ABES) · doi:10.70675/54b5d3bfzea81z4cfaza39bz7086453de3a8
Li, J., Wen, Y., Ge, F., Qiu, Y., & Xu, C. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-14482-6
“ATB was associated with a utility of 0.83, while cured or self-healing yielded a utility of 0.94, based on published estimates [29, 41, 43, 46].”
InfluentialDubée, V. (2014) · theses.fr (ABES) · doi:10.70675/146178d1z6860z4f24z87aezee075e5d4f89 · Cited by 1
Streit, E. S. (2015) · theses.fr (ABES) · doi:10.70675/f96f4de7z0522z49bbza4f6zb59bccb0bdf2
Mistretta, M. (2021) · theses.fr (ABES) · doi:10.70675/a814c67cz9630z40f6z8867z43d3267f3290
Metadata
- Authors
- Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- GGD Amsterdam (NL)
- Stellenbosch University (ZA)
- United Arab Emirates University (AE)
- Corresponding author
- Tiemersma, Edine W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-04
- Volume
- 6
- Issue
- 4
- Pages
- e17601
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3070694
- OpenAlex
- W2138041013
- Cited by
- 583
- References
- 136
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 46 · 2023: 48 · 2022: 40 · 2021: 36 · 2020: 38 · 2019: 39 · 2018: 43 · 2017: 42 · 2016: 35 · 2015: 43 · 2014: 39 · 2013: 31 · 2012: 10
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- UvA-DARE (University of Amsterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Keywords
- case fatality, disease duration, HIV-negative patients, smear-positive tuberculosis, smear-negative tuberculosis, culture-positive tuberculosis, tuberculosis prognosis
- MeSH terms
- Humans, Time Factors, Tuberculosis, Pulmonary, Survival Analysis, HIV Seronegativity, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.